Copertina

Three years of remote electrical neuromodulation (REN) acute treatment for migraine shows consistent effectiveness and no tachyphylaxis phenomenon

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Stephanie J. Nahas, Marius Birlea, Alit Stark‐Inbar, Sharon Shmuely, Eden Mama, Alon Ironi, William B. Young, Alan M. Rapoport
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Headache: The Journal of Head and Face Pain
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Novel optimization of multi‐mechanistic approaches for the acute treatment of a migraine attack: A review
di: Stephen Silberstein, et al.
Pubblicazione: (2026)

Integrating gepants into clinical practice for the acute treatment of migraine
di: Richard B. Lipton, et al.
Pubblicazione: (2026)

Remote electrical neuromodulation to treat children and adolescents with migraine in the emergency department: A randomized double‐dummy pilot trial
di: Serena Laura Orr, et al.
Pubblicazione: (2024)

Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete‐choice experiment
di: Richard B. Lipton, et al.
Pubblicazione: (2025)

Remote electrical neuromodulation for reducing procedural pain in patients with chronic migraine receiving onabotulinumtoxinA injections: A randomized sham‐controlled study
di: Nan Cheng, et al.
Pubblicazione: (2025)

The impact of headache intensity on speech in participants with migraine and acute post‐traumatic headache
di: Dani C. Smith, et al.
Pubblicazione: (2024)

Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
di: Jessica Ailani, et al.
Pubblicazione: (2024)

Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial
di: Nathaniel M. Schuster, et al.
Pubblicazione: (2025)

Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
di: Graham A. McLeod, et al.
Pubblicazione: (2025)

A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study
di: Jeffrey D. Sharon, et al.
Pubblicazione: (2024)

Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial
di: Koichi Ikeda, et al.
Pubblicazione: (2025)

Comparative analysis of real‐world acute prescription migraine therapy outcomes: Insights from the HeAD – US study
di: Devin Teichrow, et al.
Pubblicazione: (2026)

2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies
di: Jennifer Robblee, et al.
Pubblicazione: (2025)

Exploring the impact of acute SARS‐CoV‐2 infection on headache pattern in patients with migraine: A novel Bayesian analysis
di: Jiunn‐Tyng Yeh, et al.
Pubblicazione: (2025)

The 2023 protocol for update to acute treatment of adults with migraine in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies
di: Jennifer Robblee, et al.
Pubblicazione: (2024)

The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
di: Rikki Mangrum, et al.
Pubblicazione: (2024)

The effect of different exercise types on migraine frequency in individuals with migraine: A pilot study
di: Yunus Emre Meydanal, et al.
Pubblicazione: (2025)

Towards a standardized process of onboarding advanced practice providers into headache medicine practices in the United States: Expert consensus from the American Headache Society practice management committee
di: Calli Cook, et al.
Pubblicazione: (2026)

Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open‐label ASCEND acute migraine study
di: Jessica Ailani, et al.
Pubblicazione: (2025)

Evaluating associations of migraine‐related vertigo
di: Nazia Karsan, et al.
Pubblicazione: (2025)

Afterimage duration differs for migraine with or without aura
di: Florian Rimmele, et al.
Pubblicazione: (2025)

Mechanisms for mindfulness in migraine: Does catastrophizing matter?
di: Rebecca Erwin Wells, et al.
Pubblicazione: (2024)

Useful considerations for treating migraine in patients with autism
di: Sinifunanya E. Nwaobi
Pubblicazione: (2026)

Plain Language Summary Publication: The 2023 protocol for update to acute treatment of adults with migraine in the emergency department: The American headache society evidence assessment of parenteral pharmacotherapies
di: Jennifer Robblee, et al.
Pubblicazione: (2024)

Lifestyle triggers of migraine: Sleep restriction and caffeine lower the threshold for migraine‐like responses in rats in a sex‐specific manner
di: Gabriel Camargo de Oliveira, et al.
Pubblicazione: (2026)

Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study
di: Shuu‐Jiun Wang, et al.
Pubblicazione: (2024)

No association between migraine and HLA alleles in a cohort of 13,210 individuals with migraine from the Danish Blood Donor Study
di: Inga Zalia Tummoszeit, et al.
Pubblicazione: (2024)

Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
di: Chia‐Chun Chiang, et al.
Pubblicazione: (2024)

Patterns of clinical and imaging presentations in patients with spontaneous intracranial hypotension due to spinal cerebrospinal fluid venous fistula: A single‐center retrospective cross‐sectional study
di: Andrew L. Callen, et al.
Pubblicazione: (2024)

Rates and healthcare resource utilization for people with branded acute and preventive migraine prescription medication order payer denials: An open, multi‐source dataset, observational cohort study
di: Dawn C. Buse, et al.
Pubblicazione: (2026)

A 3‐year follow‐up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims‐based cohort study in the United States
di: Shivang Joshi, et al.
Pubblicazione: (2024)

Counting the cost: How migraine shapes lives and economies
di: Risako Shirane, et al.
Pubblicazione: (2025)

Cardiovascular risk and triptan usage among patients with migraine
di: Ido Peles, et al.
Pubblicazione: (2025)

Depression and anxiety are not associated with migraine outcomes in children and adolescents
di: Amy A. Gelfand
Pubblicazione: (2024)

Cognitive and emotional mechanisms underlying migraine quality of life
di: Shiri Shinan‐Altman, et al.
Pubblicazione: (2026)

Long‐term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial
di: Anna Gryglas‐Dworak, et al.
Pubblicazione: (2024)

Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo‐controlled clinical trials
di: Larry Charleston, et al.
Pubblicazione: (2026)

A retrospective analysis of the use of candesartan for migraine prevention in adolescents
di: Irene Patniyot, et al.
Pubblicazione: (2024)

Chronotype in migraine and tension‐type headache: A population study
di: Da Eun Jung, et al.
Pubblicazione: (2026)

Magnetoencephalography studies in migraine and headache disorders: A systematic review
di: Raghavan Gopalakrishnan, et al.
Pubblicazione: (2024)